- Home
- GENB vs PSNL Comparison
GENB vs PSNL Comparison
Compare GENB & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GENB | PSNL |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GENB | PSNL |
|---|---|---|
| Price | $13.42 | $11.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $23.20 | $12.20 |
| AVG Volume (30 Days) | 829.1K | ★ 5.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | $16.58 | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.00 | $3.84 |
| 52 Week High | $18.18 | $16.39 |
Technical Indicators
Market Signals| Indicator | GENB | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 43.14 |
| Support Level | $11.73 | $6.39 |
| Resistance Level | $13.76 | $12.53 |
| Average True Range (ATR) | 0.79 | 1.17 |
| MACD | -0.24 | -0.50 |
| Stochastic Oscillator | 5.08 | 1.23 |
Price Performance
Historical ComparisonAbout GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.